BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Supernus (SUPN)SupernusFDA / regulatory

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc.

Related news

CLNNClene Inc.2026-10-19 12:00 EST

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

XERSXeris Pharmaceuticals2026-09-09 12:30 EST

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

SUPNSupernus2026-09-02 20:30 EST

Supernus Pharmaceuticals to Participate in September Investor Conferences

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

JNJJohnson & Johnson2026-10-16 10:31 EST

CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-10-21 23:45 EST

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

SUPNSupernus2026-09-02 20:30 EST

Supernus Pharmaceuticals to Participate in September Investor Conferences

SUPNSupernus2026-08-31 12:30 EST

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

Stock data

Close
41.21 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States